These particles can act as active participants in this pathological process, stimulating the formation of amyloid-β (Aβ) plaques and tau tangles, and also disrupting the fragile balance in the gut–liver–brain axis, which ultimately leads to the progression of AD-associated cognitive impairments (Figure 3). The gene discussed is MAPT; the disease is Cognitive impairment.